SecProbe.io

CORRESP
1
filename1.htm

Basel
Medical Group Ltd

6
Napier Road,

Unit
#02-10/11 Gleneagles Medical Centre

Singapore
258499

Date:
December 3, 2024

Via
EDGAR

Division
of Corporation Finance

Office
of Energy & Transportation

U.S.
Securities and Exchange Commission

Washington,
D.C. 20549

    Attn.:
    Nudrat
    Salik

    Michael
    Fay

    Robert
    Augustin

    Jane
    Park

    Re:
    Basel
    Medical Group Ltd

    Amendment
    No. 2 to Registration Statement on Form F-1

    Filed
    November 14, 2024

    File
    No. 333-282096

Ladies
and Gentlemen:

Basel
Medical Group Ltd (the “Company”) hereby submits to the staff (the “Staff”) of the U.S. Securities
and Exchange Commission (the “Commission”) this letter setting forth responses to the comments contained in the Staff’s
letter dated November 27, 2024 on the Company’s Registration Statement on Form F-1 previously filed on November 14, 2024.

Concurrently
with the filing of this letter, the Company is publicly amending and refiling its registration statement on Form F-1 (the “Registration
Statement”) with the Commission.

The
Staff’s comments are repeated below in bold and are followed by our responses. We have included page references in the Registration
Statement where the language addressing a particular comment appears. Capitalized terms used but not otherwise defined herein have the
meanings set forth in the Registration Statement.

Amendment
No. 2 to Form F-1 filed November 14, 2024

Selling
Shareholders, page 3

    1.
    We
refer to your selling shareholder table on page Alt-3. Please revise your disclosure to provide additional details regarding the transaction
in which the selling shareholders acquired their shares, including the date on which the transaction was completed and the material terms
of the agreements relating to such transaction. Please file the agreements as exhibits to the registration statement or tell us why you
believe you are not required to do so. Refer to Item 601(b)(10) of Regulation S-K.

Response:
Please refer to the revised disclosure in the section titled “Selling Shareholders”. The Company submits to the Staff that
the acquisition agreements through which such Selling Shareholders acquired their shares from Rainforest Capital VCC are not material
contracts falling within the definition of such as defined in Item 601(b)(10) of Regulation S-K, as they are primarily contracts of sale
and purchase between a selling shareholder and each acquiror to sell and purchase shares of the registrant, are not contracts material
to the registrant or its subsidiaries, and create no material obligations on the registrant or its subsidiaries.

Kindly
address any comments or questions that you have concerning the Registration Statement to our attorneys Benjamin Tan Esq. and Martryn
Mak Esq. of Sichenzia Ross Ference Carmel LLP at (646) 810-0609 or btan@srfc.law and (646) 963-6393 or mmak@srfc.law.

Thank
you for your time and attention.

    Very
    truly yours,

    For
    and on behalf of

    Basel
    Medical Group Ltd

    /s/
    Raymond Wai Man Cheung

    Name:
    Raymond
    Wai Man Cheung

    Position:
    Chief
    Executive Officer